Dermatology Department, Hospital Santo António dos Capuchos, 1169-050 Lisbon, Portugal.
Eur J Dermatol. 2011 Nov-Dec;21(6):916-20. doi: 10.1684/ejd.2011.1548.
Treatment with tumor necrosis factor alpha (TNF-α) inhibitors may have favourable effects on the lipid profile. This is the first study to assess the impact of etanercept on the lipid profile in patients with moderate-to-severe plaque psoriasis. To investigate the effect of etanercept on the lipid profile after 24 weeks of treatment in patients with moderate-to-severe plaque psoriasis. We conducted a retrospective cohort study reviewing the medical records of 45 consecutive patients who were treated for psoriasis with etanercept between June 2006 and September 2009. Demographic and clinical data were collected. Levels of total cholesterol, LDL-C, HDL-C, triglycerides, fasting glucose and C-reactive protein were recorded at the start of etanercept and at week 24. Levels of total cholesterol, LDL-C and triglycerides increased after 24 weeks of treatment with etanercept, with mean differences of 7.1 mg/dL (p=0.505), 2.0 mg/dL (p=0.718) and 2.8 mg/dL (p=0.180), respectively. HDL-C decreased, with a mean difference of -1.4 mg/dL (p=0.995). None of these changes were statistically significant. We found no favourable changes on the lipid profile after 24 weeks of treatment with etanercept in responding patients with chronic plaque psoriasis.
肿瘤坏死因子-α（TNF-α）抑制剂的治疗可能对血脂谱有有利影响。这是第一项评估依那西普对中重度斑块状银屑病患者血脂谱影响的研究。评估依那西普治疗中重度斑块状银屑病患者 24 周后对血脂谱的影响。我们进行了一项回顾性队列研究，回顾了 2006 年 6 月至 2009 年 9 月期间接受依那西普治疗的 45 例连续银屑病患者的病历。收集了人口统计学和临床数据。在开始依那西普治疗时和第 24 周记录总胆固醇、LDL-C、HDL-C、甘油三酯、空腹血糖和 C 反应蛋白的水平。依那西普治疗 24 周后，总胆固醇、LDL-C 和甘油三酯水平升高，平均差异分别为 7.1mg/dL（p=0.505）、2.0mg/dL（p=0.718）和 2.8mg/dL（p=0.180）。HDL-C 降低，平均差异为-1.4mg/dL（p=0.995）。这些变化均无统计学意义。我们发现，在慢性斑块状银屑病患者中，依那西普治疗 24 周后，血脂谱没有有利变化。
